U.S. pharma large copyright scrapped two experimental weight loss drugs previous 12 months—a once-day-to-day pill, lotiglipron, resulting from elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, due to powerful side effects—but CEO Albert Bourla has claimed the company is decided to “Participate in and get” during the